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Background: The gut microbiota represents a potential treatment target in heart failure (HF) through microbial
metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic
yeast Saccharomyces boulardii have been suggested to improve left ventricular ejection fraction (LVEF).
Methods: In amulticentre, prospective randomized open label, blinded end-point trial, we randomized patients with
LVEF <40% and New York Heart Association functional class II or III, despite optimal medical therapy, to treatment
(1:1:1) with the probiotic yeast Saccharomyces boulardii, the antibiotic rifaximin, or standard of care (SoC) only. The
primary endpoint, the baseline-adjusted LVEF at threemonths, was assessed in an intention-to-treat analysis.
Findings: We enrolled a total of 151 patients. After three months’ treatment, the LVEF did not differ signifi-
cantly between the SoC arm and the rifaximin arm (mean difference was -12 percentage points; 95% CI -32
- 07; p=022) or between the SoC arm and the Saccharomyces boulardii arm (mean difference -02 percent-
age points; 95% CI -22 - 19; p=087). We observed no significant between-group differences in changes in
microbiota diversity, TMAO, or C-reactive protein.
Interpretation: Three months’ treatment with Saccharomyces boulardii or rifaximin on top of SoC had no sig-
nificant effect on LVEF, microbiota diversity, or the measured biomarkers in our population with HF.
Funding: The trial was funded by the Norwegian Association for Public Health, the Blix foundation, Stein Erik
Hagen’s Foundation for Clinical Heart Research, Ada og Hagbart Waages humanitære og veldedige stiftelse,
Alfasigma, and Biocodex.
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Research in context
Evidence before this study
The gut microbiota is altered in heart failure. A blooming of
pathological bacteria and loss of microbial diversity have been
described. These dysbiotic changes are believed to influence
the heart through gut-specific metabolites and leakage of bac-
terial products that in turn activate innate immunity. The
metabolite trimethylamine N-oxide has been associated with
adverse remodelling in heart failure, while several mediators of
innate immunity can impact cardiac function.
In a pilot study, three months treatment with the probiotic
yeast Saccharomyces boulardii improved left ventricular ejec-
tion fraction in patients with heart failure.
Added value of this study
The GutHeart study was designed to examine the effects of
microbiota modulation on cardiac function in heart failure. We
found that neither microbiota modulation with the antibiotic
rifaximin or the probiotic Saccharomyces boulardii affected car-
diac function or trimethylamine N-oxide. In fact, our interven-
tions did not significantly change the microbiota diversity.
Furthermore, our study participants were well treated and with
low symptomatic burden. The degree of dysbiosis at baseline
appeared to be low measured by the microbial diversity.
Our study suggests that broad interventions with probiotics
and antibiotics might not be sufficient to significantly alter the
microbiota in well-treated patients with heart failure.
Implications of all the available evidence
Our study suggests that not all well-treated patients with heart
failure have substantial dysbiosis. In these patients, a more pre-
cise approach targeting specific bacterial taxa or a gut-related
metabolite should be attempted.
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Heart failure (HF) with reduced ejection fraction is a progres-
sive disease with high morbidity and mortality. Contemporary
treatment of HF centres on blockade of maladaptive neurohor-
monal activation. Disturbances in metabolic and inflammatory
pathways also seem to play an important role in the development
and progression of HF, but how to modulate these mechanisms is
not clear [1,2].
Over the last two decades, research has suggested that the gut
microbiota may play a role in HF [3]. However, the causal path-
ways behind a proposed gut-heart axis remain elusive. Several
small studies have shown that the gut microbiota differs between
patients with HF and healthy subjects. Significant differences in
bacterial diversity, distribution of the main microbial phyla, spe-
cific taxa, and pathogenic microorganisms have been observed
[4,5]. At a functional level, the microbiota-related metabolite tri-
methylamine N-oxide (TMAO) is associated with increased risk of
adverse cardiovascular events and susceptibility for the develop-
ment and severity of HF [6,7]. Furthermore, the microbiota in
patients with HF may have a reduced capacity to synthesize ben-
eficial metabolites such as short chained fatty acids [8]. Short
chain fatty acids, in particular butyrate, are essential for main-
taining the mucosal barrier of the gut [9]. Loss of barrier function
might facilitate leakage of bacterial components like lipopolysac-
charides (LPS). These compounds may in turn activate the innate
immune system through pattern recognition receptors. This
mechanism may contribute to the low-grade systemicinflammation observed in HF [10-12]. Acetate and propionate,
two other short chain fatty acids, may affect the renin-angioten-
sin system through G-protein-coupled olfactory receptors, linking
the gut microbiota to activation of neurohormonal pathways in
HF [13]. Acetate has also been shown to decrease cardiac hyper-
trophy, attenuate cardiac fibrosis, and improve cardiac function in
experimental studies [14].
In a small pilot trial, Costanza and colleagues randomly assigned
20 patients with HF with reduced ejection fraction to treatment with
the probiotic yeast Saccharomyces boulardii (S.boulardii) or placebo
[15]. The left ventricular ejection fraction (LVEF) increased more in
the active treatment arm. However, the small size of the study and
the lack of data on associated changes in the gut microbiota limit our
ability to draw conclusions regarding causality.
In the Targeting Gut Microbiota to Treat Heart Failure (GutHeart)
trial, we aimed to explore the effect of S.boulardii or the oral non-
absorbable antibiotic rifaximin on top of guideline-recommended
treatment for HF with reduced ejection fraction. In this proof-of-con-
cept study, we also aimed to assess the effects of the microbiota-
directed treatment on the composition and function of bacteria in the
gut, on the key microbial metabolite trimethylamine N-oxide
(TMAO), and on systemic inflammation.2. Methods
2.1. Study design
The GutHeart trial (www.clinicaltrials.govNCT02637167) is a
phase II, multicenter, randomized, open label, controlled trial. The
trial was conducted at three hospitals in Norway and one hospital in
Brazil. Participants were randomly assigned in a 1:1:1 fashion. Both
interventional arms were compared to the standard of care (SoC)
arm.
The trial complies with the declaration of Helsinki. The Regional
Ethics Committees approved the trial (reference No 2015/120/REK
sør-øst) and all subjects gave their written informed consent to par-
ticipate. Independent data monitors oversaw the study [16].2.2. Participants
We recruited patients from the outpatient clinics at Oslo Univer-
sity Hospital Rikshospitalet (Oslo, Norway), Oslo University Hospital
Ulleva l (Oslo, Norway), Nordlandssykehuset (Bodø, Norway), and
Instituto Nacional de Cardiologia (Rio de Janeiro, Brazil). We enrolled
patients with symptomatic HF in New York Heart Association func-
tional class II, III, and LVEF < 40 % at the time of inclusion. The partici-
pants had to be on optimal medical treatment for three months prior
to inclusion. This includes maximally tolerable doses of angiotensin
converting enzyme inhibitors/angiotensin receptor antagonists/
angiotensin receptor-neprilysin inhibitors, beta-blockers, and miner-
alocorticoid receptor antagonists if indicated, according to ESC guide-
lines for the diagnosis and treatment of acute and chronic heart
failure 2016 [17].
Key exclusion criteria were: treatment with antibiotics or probiot-
ics during the last three months prior to inclusion, significant comor-
bidities, treatment with immunosuppressive drugs, concurrent
infections, or bowel disease. Patients who had received cardiac
resynchronization therapy during the past six months were not
included. A complete list of inclusion and exclusion criteria is pro-
vided in Supplementary Table 1.
Diet is a known major modulator of the gut microbiome. We
therefore encouraged all patients not to change their dietary habits
during the study period. All patients were equipped with a list of pro-
biotics and food enriched with probiotics, which they were asked to
refrain from during the study period.
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The research support unit at Oslo University Hospital generated a
balanced, permuted block randomization list with varying block
sizes. The randomization was stratified by center. We performed
treatment allocation on the online platform Viedoc TM (PCG Solutions,
Uppsala, Sweden). The study was open label with blinded endpoint
analyses.
2.4. Interventions
Patients eligible for participation were randomized to oral treat-
ment with 550 mg of the non-absorbable antibiotic rifaximin twice a
day, two capsules of 250 mg of the probiotic yeast S.boulardii (CNCM
I-745) twice a day, or conventional treatment for HF only. All inter-
ventions were given on top of SoC. The intervention period lasted
three months. Patients were asked not to ingest probiotics and food
enriched with probiotics during the study period. Follow-up visits
were scheduled at month one and three. We consecutively registered
all adverse events. Serious adverse events were defined as an event
that resulted in death, was immediately life-threatening, required in-
patient hospitalization, or prolongation of existing hospitalization,
resulting in persistent or significant disability or incapacity, or an
important medical event that may jeopardize the subject or may
require medical intervention to prevent one of the outcomes listed
above.
An independent safety committee oversaw the safety of the trial
and assessed all serious adverse events.
2.5. Study endpoints
The primary endpoint was LVEF after three months of interven-
tion after adjustment for baseline values. The secondary endpoints
were baseline-adjusted N-terminal pro-B-type natriuretic peptide
(NT-proBNP), high sensitivity C-reactive protein (CRP), TMAO,
changes in the composition of the microbiota (Shannon index, ampli-
con sequence variants (ASVs), and other compositional changes).
2.6. Echocardiography
We used a standardized protocol for image acquisition as recom-
mended by the European Association of Cardiovascular Imaging [18].
Echocardiograms were digitally stored and analysed offline in Echo-
Pac version 202 pc. We de-identified the exams and assigned a ran-
dom identification number to each individual exam. Image analysis
was performed at the core lab facility at Oslo University hospital,
Oslo, Norway by personnel blinded to treatment allocation and to
whether the exam was performed at baseline or follow-up. Due to
data storage problems, which occurred at one study site, approxi-
mately 10% of the echocardiograms were analysed at the local study
site. We performed sensitivity and validation analysis on these data.
Left ventricular volumes were calculated using the modified Simp-
son’s rule[19]. We used apical four chamber views in combination
with two-chamber views unless the three-chamber view was supe-
rior in terms of endocardial border definition.
2.7. Microbiota analyses
At inclusion, all patients received a stool collection device and
careful instructions on how to collect the samples. They collected
samples immediately prior to and at the end of the intervention
period. The samples were delivered in person or by postal mail. All
samples were collected in tubes with a deoxyribonucleic acid (DNA)
stabilizing solution (PSP Spin Stool DNA kit, Stratec Molecular GMBH,
Berlin, Germany). We registered the time from collection to freezer
for all samples.Stool DNA was extracted using the PSP Spin Stool DNA Plus
extraction (Stratec Molecular) kit with a protocol modified by adding
a bead-beating step, as described elsewhere [20]. The V3V4 region
of the 16S ribosomal ribonucleic acid (rRNA) gene was amplified and
libraries sequenced on the Illumina MiSeq platform (San Diego, Cali-
fornia, USA) at the Norwegian Sequencing Centre (Oslo, Norway), as
previously described in detail [5].
Paired-end reads were filtered for Illumina Universal Adapters
and PhiX, demultiplexed, quality trimmed, and merged using BBDuk
3886, Cutadapt 210, and BBMerge 3886[21-23]. Denoising to
ASVs, taxonomic classification and filtering of contaminants and rare
ASVs were done with QIIME2 version 20208 [24]. There were no
detectable levels of bacteria in the negative controls, and conse-
quently, no identified contaminants were removed from the dataset
before further analyses were performed.
To reduce the effect of heterogeneous sequencing depths, we
rarefied all samples to a common level of 7952 reads. We calculated
diversity values and tested for differential abundance with this rare-
fied dataset.
In a subset of patients we estimated the butyrate producing
capacity of the microbial communities by the abundance of the Buty-
rate-acetoacetate CoA transferase gene encoding the rate-limiting
step. This represents the capacity of the microbiota to produce buty-
rate. We used PICRUST2 with default settings on all included samples
[25].
2.8. Circulating biomarkers
The patients fasted overnight before we collected blood samples
by venipuncture. Samples were collected at baseline and after three
months. We separated serum and EDTA-plasma within 1h by centri-
fugation at room temperature and at 4°C, respectively, and stored the
samples at 80°C until analyses. NT-ProBNP was determined by an
electrochemiluminesence immunoassay (ECLIA) (Roche Diagnostics,
Mannheim, Germany), plasma TMAO by stable isotope dilution liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as previ-
ously described[26], and CRP was analysed by ELISA (DRG Instru-
ments, Marburg/Lahn, Germany). Intra-assay coefficients of variation
were 69% for CRP, 5% for NT-proBNP, and 41% for TMAO.
2.9. Six minute walk test
A six minute walk test was performed at baseline and at 3 months.
The patients were asked to bring appropriate clothing and shoes for
the test. They rested in a chair for at least 10 minutes before the test
started. The patients were encouraged to make his/her best effort
during the six minute test. Heart rate and arterial oxygen saturation
was recorded at the beginning of the exercise, and again at the end of
the exercise after six minutes. We recorded the walking distance and
any premature interruption of the test.
2.10. Statistics
We analysed the data according to the intention-to-treat princi-
ple. As we were not able to obtain endpoints at 3 months for all
patients, we used the full analysis set strategy. The intention-to-treat
population is defined as all participants who were randomized
regardless of adherence to study drug or follow-up. The per-protocol
population is defined as cases with more 80% self-reported investiga-
tional drug compliance. We also excluded 15 patients where LVEF
was calculated at the local study site and not at the designated core
lab in a modified intention-to-treat analysis. We performed sensitiv-
ity analyses for both per-protocol and modified intention-to-treat
cases.
The trial was powered to detect a 5 percentage points increase in
LVEF in either intervention group compared with the SoC arm, with
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of LVEF of 75 percentage point, 37 patients would be needed in each
group. To compensate for dropouts, we intended to include 50
patients in each group, in total 150 patients.
The primary endpoint was analysed with analysis of covari-
ance (ANCOVA), comparing LVEF after three months between
either intervention group and the SoC arm. We adjusted for base-
line LVEF. We also used ANCOVA to determine the effect of our
interventions on the Shannon Index, ASVs, the abundance of the
Butyrate-acetoacetate CoA transferase gene, NT-proBNP, CRP, and
TMAO.
Paired sample t-tests or Wilcoxon signed-rank tests were used to
explore within-group treatment effects. We log-transformed TMAO,
CRP, NT-proBNP, and the abundance of Butyrate-acetoacetate CoA
transferase gene because the raw data were skewed.
When we analysed microbiota data at genus level, only significant
within-group and between-group differences were reported. Wil-
coxon signed-rank tests were used to explore the genus-level
within-group treatment effects. P-values were adjusted using the
Benjamini-Hochberg False Discovery Rate. Differences between the
treatment groups were tested using Mann-Whitney-Wilcoxon on the
delta values.
We used IBM SPSS statistics version 250 to perform all statistics.
Data are presented as means (+/-standard deviation), medians (inter-
quartile range) or number (percent) unless stated otherwise.
2.11. Role of the funding sources
The funding sources had no role in the design of the trial, data col-
lection, analysis, and interpretation, writing of the manuscript, or the
decision to publish.Fig. 1. CONSORT Flow diagram. S.bou3. Results
3.1. Enrollment and baseline characteristics
From March 11th, 2016 to May 16th, 2019, we enrolled 151
patients, 124 in Norway, and 27 in Brazil. The last patient completed
the three-month follow-up August 30th, 2019. Forty-eight patients
were allocated to rifaximin, 52 patients to S.boulardii, and 51 patients
were assigned to conventional treatment only. One hundred thirty-
two patients were analysed for the primary and secondary endpoints
(Fig, 1). The characteristics of the study population are presented in
Table 1. Baseline characteristics were balanced between the groups.
Heart failure drug regimens remained stable during the study
period. We recorded minor adjustments in either mineralocorticoid
receptor antagonists, beta-blockers, or angiotensin converting
enzyme inhibitors/angiotensin receptor antagonists/angiotensin
receptor-neprilysin inhibitors in eight patients. Six patients either
initiated loop diuretics or adjusted their doses of loop diuretic.
3.2. Primary endpoint
After three months’ intervention, the mean LVEF was 296 (73)
percent in the rifaximin arm, 303 (63) percent in the S.boulardii
arm, and 315 (86) percent in the SoC arm. The baseline-adjusted
difference between the rifaximin and the SoC arm was 12 percent-
age points (95% CI -07 - 32, P=022) (Fig. 2) and 02 percentage
points (95% CI -19 - 22, P=087) between the S.boulardii arm and
the SoC arm (Fig. 2).
Changes within all treatment arms are shown in Fig. 2. Analyses of
modified intention-to-treat and per-protocol cases did not change
the results (Table 2).lardii = Saccharomyces boulardii.
Table 1







Age (years) (SD) 59(10) 62(8) 60(10)
Female gender  n (%) 13(27) 10(20) 13(27)
Body mass index (kg/m2) (SD) 28(5) 29(5) 28(4)
Systolic BP. (mm Hg) (SD) 118(21) 119(20) 123(20)
Diastolic BP (mm Hg) (SD) 72(11) 72(11) 75(11)
Heart rate (beats/minute) (SD) 66(12) 66(10) 69(11)
Atrial fibrillation/flutter  n (%) 11(23) 20 (39) 16(33)
NYHA class II/III  n (%) 31 (65)/17(35) 36 (71)/15(29) 39 (80)/10(20)
Medical history
Ischemic etiology  n (%) 28(58) 30(59) 26(53)
History of smoking  n (%) 21(44) 13(26) 21(43)
History of hypertension  n (%) 17(35) 19(37) 29(47)
Diabetes mellitus  n (%) 14(29) 15(29) 12(25)
Implantable cardioverter defibrillator only  n (%) 12(25) 12(24) 18(37)
Cardiac resynchronization therapy  n (%) 15(31) 21 (41) 17(35)
Heart failure medication  n (%)
ACE inhibitor/ARB 47 (98) 50 (98) 43 (88)
Sacubitril/Valsartan 8(17) 9(18) 4(8)
Beta blocker 46 (96) 51 (100) 44 (90)
Mineralocorticoid receptor antagonist 24 (50) 34 (67) 37(63)
Diuretics 35(73) 29(57) 28(57)
Laboratory values
Hemoglobin (g/dL) (IQR) 145 (139 - 155) 146 (135 - 156) 145 (135 - 153)
eGFR (IQR) 72 (58 - 86) 65 (47 - 83) 73 (57 - 90)
N-terminal-pro-B-type natriuretic peptide (pg/mL) (IQR) 1241 (515 - 1707) 811 (387 - 1618) 853 (435 - 1893)
C-reactive protein (mg/L) (IQR) 148 (074 - 344) 179 (070 - 347) 142 (061 - 481)
TMAO (mmol/L) (IQR) 610 (407 - 1054) 700 (440 - 1277) 600 (363 - 1121)
Diversity measures
Shannon diversity index (IQR) 552 (480 - 584) 542 (491 - 586) 562 (495 - 589)
Amplicon sequence variants 222 (185 - 270) 219 (175 - 264) 231 (202 - 269)
Echocardiography
Left ventricular ejection fraction (%) (SD) 28(7) 30(6) 31(6)
Data are given as number (percent), mean (standard deviation), or median (interquartile range) as appropriate.
SD = Standard deviation, IQR = interquartile range, NYHA class = New York Heart Association functional class, ACE-I = Angiotensin converting
enzyme inhibitor, ARB = Angiotensin II receptor blocker, eGFR= estimated Glomerular Filtration Rate, TMAO = Trimethylamine N-oxide,
SoC = Standard of care.
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There were no significant differences in the levels of NT-proBNP,
CRP, or TMAO after three months for any of the intervention groups
versus SoC (Fig. 3). NT-proBNP increased from baseline to three
months in the S.boulardii arm, but not in the rifaximin arm or in the
SoC arm (Fig. 3). Neither TMAO nor CRP changed significantly from
baseline to three months in any group (Fig. 3).
In total, 135 patients were included in the microbiota analyses.
Twenty-one from Brazil and 114 from Norway. We observed no signifi-
cant differences in global microbiota composition (beta diversity) or
bacterial richness (alpha diversity) from baseline to the end of the
intervention between either of the intervention groups and SoC (Fig. 3).
However, there were False Discovery Rate corrected changes in several
bacterial genera in the rifaximin arm. The genus Clostridia_UCG-014,
Christensenellaceae_R-7_group, and Clostridiales family XIII were signifi-
cantly reduced, and Flavonifractor, was significantly increased com-
pared to SoC. In contrast, there were no compositional changes in the S.
boulardii arm or in the SoC arm (Supplementary Fig. 1).
Furthermore, we analyzed the abundance of the Butyrate-acetoa-
cetate CoA transferase gene at 3 months in the Norwegian study par-
ticipants. We found no difference in levels at 3 months between
groups (SoC vs rifaximin, log mean difference -005, 95% CI -031 -
022, P=073 and SoC vs S.boulardii, log mean difference 022, 95% CI
-005 - 048, P=010).
Finally, we found no significant differences in the six minute walk
test performance. The baseline-adjusted difference was 68 meters(95% CI -125 - 261, P =048), between the rifaximin and the SoC
arm and 74 meters (95% CI -107 - 254, P=042), between the S.
boulardii and the SoC arm.
3.4. Compliance
Compliance was measured by counting the number of tablets
returned at the 1-month and 3-month visits. Forty patients (83%) in
the rifaximin arm and 41 patients (80%) in the S.boulardii arm had a
per-protocol study drug compliance above 80%. In the rifaximin
group, the within-group change in bacterial richness was used as an
indirect measure of compliance. There was a significant reduction
from baseline to the end of intervention (Fig. 3), as expected based
on previous experiences [27]. In the S.boulardii group, visual inspec-
tion of an end-point PCR specific for the S.boulardii TY Delta element
was performed as a coarse measure of compliance, revealing a visible
band in the majority of the S.boulardii group and only in a small num-
ber of the control group at 3 months (Supplementary text 1).
3.5. Safety
Safety endpoints are defined in supplementary text 2.
Eight patients stopped the study medication due to side effects,
three participants in the rifaximin arm and five in the S.boulardii arm.
Abdominal pain, obstipation, diarrhea, and bloating were the main
causes of discontinuation. One patient developed an allergic exan-
thema on the torso while two patients experienced acute dyspnea as
Fig. 2. Baseline-adjusted mean LVEF and within-group changes in LVEF. (Graph a) The graphs shows individual and within-group change in LVEF from baseline to 3 months. (Graph
b) The bars indicates baseline-adjusted mean at 3 months. The upper panel shows rifaximin vs control and the lower panel shows S.boulardii vs control. The notation above the bars
indicates the p-value for difference between the values. LVEF = Left ventricular ejection fraction. S.boulardii = Saccharomyces boulardii. SoC = Standard of care.
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the study drug.
There were nine serious adverse events, four of which occurred in
the rifaximin arm, two in the S.boulardii arm, and three in the SoC
arm. In the rifaximin arm, three patients experienced shortness of
breath, two of whom were admitted to the hospital for stabilization.
The third patient was treated by his primary physician. All patients
recovered after diuretic treatment. The third patient died three
months after the event. The death was out of hospital and not wit-
nessed. One patient in the rifaximin arm received appropriate treat-
ment from his implantable cardiac defibrillator. Two of the serious
adverse events were adjudicated to be “not related to the investiga-
tional drug” by the independent safety committee, while the other
two were adjudicated to be “probably not related to the investiga-
tional drug”.Table 2
Sensitivity analysis of adjusted mean difference in left ventricu
Analysis Rifaximin vs SoC
ANCOVA (baseline-adjusted mean diff
N Mean (95% CI) P-v
Per- protocol 83 11 (-093 - 314) 02
Intention-to-treat 87 114 (-083 - 312) 02
Intention-to-treat* 75 058 (-156 - 272) 05
Per-protocol is defined as cases with more than 80% study dru
with full data set (full analysis set). *Indicates intention-to-tr
ejection fraction was not calculated at the designated core lab
care.In the S.boulardii arm, one patient was hospitalized due to pul-
monary edema related to a paroxysm of atrial fibrillation. He
spontaneously converted to sinus rhythm and improved with
diuretic treatment. The patient was later hospitalized due to
melena and an International Normalized Ratio (INR) of 64 during
warfarin treatment. Another patient in the S.boulardii arm was
hospitalized with dyspnea. He recovered after intensified diuretic
treatment. Both were adjudicated as “probably not related to the
investigational drug”.
In the SoC arm, one patient was hospitalized with ventricular
tachycardia and syncope. He received an appropriate shock from his
implantable cardiac defibrillator and was discharged the following
day. One patient was hospitalized with pneumonia and ventricular
tachycardia. One patient was hospitalized with dyspnea and concur-
rent atrial flutter. He responded well to rate control and intensifiedlar ejection fraction.
S.boulardii vs SoC
erence ANCOVA (baseline-adjusted mean difference
alue N Mean (95% CI) P-value
8 85 051 (-158 - 261) 063
5 91 017 (-185 - 218) 087
9 84 007 (-20 - 213) 095
g compliance. Intension-to-treat indicates all participants
eat analysis excluding 15 subjects where left ventricular
. S.boulardii = Saccharomyces boulardii, SoC = Standard of
Fig. 3. Baseline-adjusted microbiota diversity (upper panel a) and circulating biomarkers (lower panel b). The bars within each sector show baseline levels vs levels after three
months for all groups. The notation above the thin brackets indicates p-value for within-group change. The notation above the thick brackets indicates the p-value for difference
between baseline-adjusted mean after three months for investigational drugs vs control. The p-value above the thin brackets indicate within-group differences. CRP = C-reactive
protein. NT-proBNP = N-terminal pro-B-type natriuretic peptide. S.boulardii = Saccharomyces boulardii. SoC = Standard of care. TMAO = Trimethylamine N-oxide.
A. Awoyemi et al. / EBioMedicine 70 (2021) 103511 7HF medications. All events in the SoC arm were adjudicated as “not
related to the GutHeart trial”.
4. Discussion
In the GutHeart trial, we aimed to investigate if modulation of the
gut microbiota could improve cardiac function in patients with HF
with reduced ejection fraction. Three months of intervention with
the probiotic yeast S.boulardii or the locally acting oral antibiotic
rifaximin had no effect on LVEF.
Furthermore, the interventions had no effect on any of the secondary
endpoints related to cardiac function, exercise capacity, systemic
inflammation, and global microbiota function, or composition. However,
in the rifaximin group the composition of themicrobiota changed signif-
icantly from baseline to the end of the intervention. These changes com-
prised a reduction of three commensals and an increase in one
commensal in the class of Clostridia. We cannot rule out that there were
more changes further down the phylogenetic tree or that our interven-
tions impacted the gut metagenome. However, none of these potential
effects were transferable into any detectable clinical change or increase
in the butyrate producing capacity of the microbiota.
The rationale for the trial was based on the premise that the inter-
ventions would improve cardiac function by affecting microbiota
composition and to subsequently modulate metabolic pathways and
gut-related inflammation. However, no evidence of such effects was
found in this trial.
We chose S.boulardii as an investigational drug because a pilot
trial comprising 20 Brazilian patients with HF showed that interven-
tion with S.boulardii was associated with a decrease in CRP levels and
an increase in LVEF [15]. The other investigational drug was rifaxi-
min, an oral antibiotic with bactericidal activity against a broad array
of enteric pathogens. Oral antibiotics have been reported to decrease
levels of TMAO in animal models [28]. Both drugs have microbiota-restoring effects in conditions associated with dysbiosis and they
have been shown to promote butyrate producers in the gut [29-31].
One could speculate if the different dietary and genetic back-
ground between the Norwegian and Brazilian participants might
have affected our results. However, as dysbiosis has been demon-
strated in heart failure patients in different European as well as Asian
populations, we believed that a potential effect is independent of die-
tary patterns or genetic background [8,32,33].
The degree of dysbiosis is associated with the burden of symp-
toms in HF [4]. Despite the reduced ejection fraction, most of our
patients were in NYHA class II, and the median plasma concentra-
tion of NT-proBNP was as low as 964 pg/mL. This corresponds
well to a surprisingly high microbiota alpha diversity at baseline
compared to that observed in other HF cohorts in which the
patients were more symptomatic as evaluated by NYHA-class,
had higher levels of NT-proBNP, and used more diuretics [32,34].
Substantial dysbiosis may be a prerequisite for observing eubiotic
effects of our interventions.
Several factors, such as diet and commonly used drugs for cardio-
vascular disease, can influence the composition of the gut microbiota
[35,36]. These factors could have confounded our results. However,
drugs for HF were evenly distributed across groups (Table 1), and the
patients were asked not to change their dietary habits during the
intervention period.
Safety concerns have been raised regarding treatments targeting
the gut microbiota in HF [37,38]. Importantly, we observed no signifi-
cant difference in the number or severity of serious adverse events
between the intervention groups and the SoC group. Treatment side
effects were mild and reversible.
Our trial has several limitations. The main shortcoming is the
open label design. Matching placebo products were difficult to obtain
due to costs and the distinct smell of yeast of S.boulardii capsules.
However, analyses of the predefined endpoints (LVEF, the microbiota
8 A. Awoyemi et al. / EBioMedicine 70 (2021) 103511composition and function, and circulating biomarkers) were per-
formed in a blinded fashion.
Fecal microbiota transplantation (FMT) represents an interesting
interventional concept in microbiota modulation, and would be very
interesting as a treatment arm in this trial. However, due to conceiv-
able challenges in study conduction, we opted not to use this form of
intervention.
The study was powered to detect a 5 percentage points
increase in LVEF; thus, we cannot rule out that a more subtle
treatment effect could have been detected in a larger trial. How-
ever, the lack of treatment effects both on the diversity of the
microbiota composition and on cardiac function strongly suggests
that treatment with S.boulardii or rifaximin did not confer a bene-
fit over SoC in our patients with HF.
A major limitation to this trial is that we only have crude meas-
ures of study drug compliance. Nevertheless, at group level we
observed changes in the microbiota in the rifaximin arm, and we
detected S.boulardii DNA in feces in the S.boulardii arm. Combined
with a self-reported compliance of about 80%, this suggests that the
overall adherence was good..
In conclusion, three months’ intervention with S.boulardii or
rifaximin had no clinically significant effect on LVEF, microbiota
diversity and function, circulating levels of TMAO, or systemic
inflammation in HF with reduced ejection fraction. The treatment
was well tolerated.
Our study suggests that optimally treated patients with HF with
reduced ejection fraction does not necessarily have a large degree of
dysbiosis. Consequently, microbiota modulation using broad-spec-
trum antibiotics such as rifaximin or unspecific probiotics such as S.
boulardiimay not be feasible in such patients.
When devising future strategies for targeting the gut-heart axis in
HF, one should tailor treatment according to the degree of dysbiosis
or directly target specific taxa or metabolites of importance.
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